Interim report for fourth quarter 2020, 1 January – 31 December 2020

Fourth quarter in brief as well as the period 1 January – 31 December 2020Net sales for the period (January to December) amounted to SEK 0,1 million (3,2 million), of which the fourth quarter contributed SEK 0 million (0 million).R&D costs for the period amounted...

Agreement on development of HDAC6 inhibitors discontinued.

Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for the development of Kancera's series of HDAC6 inhibitors...